Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US-9522123-B2 · Dec 20, 2016 · US
Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US10799467B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10799467-B2 |
| Application number | US-201514685753-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 14, 2015 |
| Priority date | Mar 30, 2010 |
| Publication date | Oct 13, 2020 |
| Grant date | Oct 13, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of partial seizures, which comprises administering to a subject in need thereof a therapeutically effective amount of the phytocannabinoid CBDV, wherein the CBDV is present as the only active cannabinoid. 2. The method of claim 1 , wherein the partial seizure to be treated is a temporal lobe seizure. 3. The method of claim 1 , wherein the CBDV is used in combination with a standard anti-epileptic drug. 4. The method of claim 3 , wherein the standard anti-epileptic drug is phenobarbital. 5. The method of claim 3 , wherein the standard anti-epileptic drug is ethosuximide. 6. The method of claim 3 , wherein the standard antiepileptic drug is valproate.
Assignees
Inventors
Classifications
Cannabis · CPC title
- A61K31/658Primary
o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title
Antiepileptics; Anticonvulsants · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10799467B2 cover?
- This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate o…
- Who is the assignee on this patent?
- Gw Pharma Ltd, Otsuka Pharma Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/658. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).